Repaglinide

CAS NO: 135062-02-1
Molecular Formula: C₂₇H₃₆N₂O₄
Molecular Weight: 452.585740 g/mol
Index of Refraction: 1.567
Surface Tension: 47 dyne/cm
Density: 1.137 g/cm³
Flash Point: 360.8 °C
Enthalpy of Vaporization: 103.84 kJ/mol
Boiling Point: 672.9 °C at 760 mmHg
Vapour Pressure: 5E-19 mmHg at 25°C
Melting Point: 129-130.2 °C
Storage temp: 2-8°C
Solubility DMSO: 34 mg/mL
Appearance: White to off-white solid
Molecular Structure: 
IUPAC Name: 2-Ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
Synonyms of Repaglinide (CAS NO.135062-02-1) : (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid ; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid ; Prandin ; Repaglinida ; Repaglinidum ; Benzoic acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-, (S)-
Product Categories: Pharmaceutical material and intermeidates;Active Pharmaceutical Ingredients;Chiral Reagents;Amino Acids 13C, 2H, 15N;Chemical Impurities;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals;Amino Acids & Derivatives

The drug was the first of the meglitinide class, which was later licensed by Boehringer to Novo Nordisk, which filed an Investigational New Drug application for the compound with the Food and Drug Administration (FDA) in April 1992. Novo Nordisk filed its New Drug Application (NDA) for Prandin in July 1997 and it was quickly approved, gaining FDA approval in December 1997. . Repaglinide (CAS NO.135062-02-1) was branded Prandin because its quick onset and short duration of action concentrates its effect around meal time (the prandium was the Roman meal which is comparable to the modern lunch).

 Repaglinide (CAS NO.135062-02-1) is used for the treatment of type II diabetes. It belongs to the meglitinide class of blood glucose-lowering drugs.

WGK Germany: 2
RTECS: 000000033825

 Repaglinide (CAS NO.135062-02-1) should not be administered concomitantly with gemfibrozil, clarithromycin or azole antifungals such as itraconazole or ketoconazole.Administration of both repaglinide and one or more of these drugs results in an increase in plasma concentration of repaglinide and may lead to hypoglycemia.